Company / SG&A Expense
Akebia Therapeutics, Inc. SG&A Expense History
FY2014-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$107.5M
FY2025
5-year range
$100.2M / $149.5M
FY2021-FY2025
Trend
+0.9%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Increased from $100M to $107M over the past 2 years.
Based on SEC 10-K filings.
$107M in FY2025 with a 10-year CAGR of +31.4%.
Increased from $100M to $107M over the past 2 years.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- -8.1%
- 5-Year CAGR
- +4.3%
- 10-Year CAGR
- +31.4%
Key checks
Key Insights
- 5-year CAGR of +4.3%, indicating consistent growth.
- In FY2025, sg&a expense increased 0.9% year-over-year.
- Peak sg&a expense was recorded in FY2021.
- Lowest sg&a expense in the period was in FY2014.
Company context
Key Data Points
- Altman Z-Score -2.76 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $107.5M | +0.9% |
| FY2024 | $106.5M | +6.3% |
| FY2023 | $100.2M | -27.7% |
| FY2022 | $138.6M | -7.3% |
| FY2021 | $149.5M | +71.7% |
| FY2020 | $87.1M | +222.4% |
| FY2019 | $27.0M | +21.6% |
| FY2018 | $22.2M | +215.9% |
| FY2015 | $7.0M | +143.2% |
| FY2014 | $2.9M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026